Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04013672
Title Phase II Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Manmeet Ahluwalia, MD
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.